APC 2010 Agenda
Drug Discovery in the 21st Century
Drug Discovery in the 21st Century
MONDAY, 24 MAY 2009
| Session | Topic | Speaker | Company | Time |
|---|---|---|---|---|
| Registration | REGISTRATION and Continental Breakfast | 7:30 - 8:30 |
MONDAY, 24 MAY 2010
| Session | Topic | Speaker | Company | Time |
|---|---|---|---|---|
| Conference Opening | Mark Duggan | 8:30 - 8:45 | ||
| Session I: | Alternative Approaches to Drug Discovery I | |||
| Diversity-Oriented Synthesis Yields a Unique Compound Collection for Probe Development and Drug Discovery | Mark Foley | The Broad Institute | 8:45 - 9:35 | |
| Chemical Control Over the Hsp70 Complex Reveals Its Roles in Tauopathy | Professor Jason Gestwicki | University of Michigan | 9:35 - 10:25 | |
| Break | 10:25 - 10:40 | |||
| Drug-Target Residence Time: Implications for Drug Efficacy, Pharmacodynamics and Safety | Robert Copeland | Epizyme, Inc. | 10:40 - 11:30 | |
| Lunch | 11:30 - 12:30 | |||
| Session II: | Enabling Technologies | |||
| Organizer Introduction | David Kimball | 12:30 - 12:40 | ||
| Encoded Library Technology: A New Approach to Lead Discovery | Barry Morgan | GlaxoSmithKline | 12:40 - 1:30 | |
| The Use of Gene Knock-Outs to Select Novel Targets and Guide the Discovery and Development of New Drugs | Alan Main | Lexicon Pharmaceuticals | 1:30 - 2:20 | |
| Break | 2:20 - 2:35 | |||
| Enabling Discovery and Preclinical Compound Progression Using Amorphous Dispersions and in silico Pharmacokinetic Predictions | David Lyon | Bend Research | 2:35 - 3:25 | |
| Imaging Drug Action in the Human Brain | Joanna Fowler | Brookhaven National Lab | 3:25 - 4:15 | |
| Evening Reception | 4:15 - 5:15 | |||
| Keynote Address - Drugging the Undruggable | Professor Gregory Verdine | Harvard University | 5:15 - 6:15 | |
| Speaker Dinner | The Asgard | 7:00 - 9:00 | ||
TUESDAY, 25 MAY 2010
| Session | Topic | Speaker | Company | Time |
|---|---|---|---|---|
| Session III: | Tackling Rare Disease | |||
| Organizer Intro | Brian Jones | 8:30 - 8:40 | ||
| Discovery and Optimization of Bone Morphogenetic Protein (BMP) Signaling Inhibitors | Greg Cuny | LDDN, Harvard | 8:40 - 9:30 | |
| Drug Discovery in an Academic Setting; Recycling Enzyme Targets | Paul Wyatt | Dundee Drug Discovery Unit | 9:30 - 10:20 | |
| Break | 10:20 - 10:40 | |||
| Discovery of DcpS as a Novel Therapeutic Target for Spinal Nuscular Atrophy | Mark E. Gurney | 10:40 - 11:30 | ||
| New Drug Classes for the Treatment of Mycobacterium Tuberculosis Infection | Mark Mitton-Fry | Pfizer | 11:30 - 12:20 | |
| Lunch | 12:20 - 1:10 | |||
| Session IV: | Alternative Approaches to Drug Discovery II | |||
| Organizer Intro | Youssef Bennani | 1:10 - 1:20 | ||
| Identification of a PDE9 Clinical Candidate for the Treatment of Alzheimer’s Disease Utilizing Prospective Design and Novel Library Protocol Development | Patrick Verhoest | Pfizer | 1:20 - 2:10 | |
| Discovery of CFTR Modulators for the Treatment of Cystic Fibrosis | Sabine Hadida | Vertex | 2:10 - 3:00 | |
| Dual Acting Receptor Antagonist (DARA) - A Case Study | David Floyd | 3:00 - 4:00 | ||